Analyst Conference Summary

biotechnology

conference date: May 1, 2025 @ 5:30 AM Pacific Time
for quarter ending: March 31, 2025 (first quarter, Q1)

Forward-looking statements

Overview:

Basic data (GAAP):

Revenue was $ million, up % sequentially from $593 million, and up % from $ million year-earlier.

Net income was negative $ million, up sequentially from negative $84 million, and down from negative $ million year-earlier.

Diluted EPS was negative $, up sequentially from negative $0.65, and up from negative $ year-earlier.

Guidance:

Conference Highlights:

Yvonne Greenstreet, CEO of Alnylam, said: "" Expects to achieve non-GAAP profitability by end of 2025.

In Q4 2024 announced positive results from Phase 1 study of mivelsiran for Alzheaimer's disease. Showed lowering of sAPPB, which should lower amyloid production.

Amvutra (Vutrisiran) Phase 3 ATTR amyloidosis with cardiomyopathy approved by FDA in March 2025. Positive topline results (Helios-B) were reported in July 2024. Expects to launch in U.S. in early 2025. Believes in the global market 80% of potential ATTR-CM patietns are undiagnosed.

In March 2025 fitusiran for hemophilia A or B was approved by the FDA.

Net revenue from collaborations was $ million, down from $ million year-earlier. Royalty revenue was $ million, up from $ million year-earlier.

Non-GAAP net income $ million, up sequentially from $8.0 million, and up from negative $ million year-earlier. EPS $, up sequentially from $0.06, and up from negative $ year-earlier.

Cash and equivalents balance at the end of the quarter was $ billion, down sequentially from $2.69 billion. Convertible Debt $1.0 billion.

See also Alnylam pipeline. In Q1 2025 had 20 clinical programs including 10 in late stages.

Operating expenses of $ million consisted of: $ million for cost of goods sold; $ million for research and development; and $ million for general and administrative expense; $0 million cost of collaboration. Operating loss $ million. Interest & other expense was $ million. $ million income tax.

Q&A Selective Summary:

OpenIcon Alnylam page

OpenIcon Analyst Conference Summaries Main Page

Search

More Analyst Conference Pages: